The introduction of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable buzz within the medical community. This novel dual GIP and GLP-1 target medication seems to offer significant improvements in weight loss compared to existing therapies. Preliminary patient data have shown significant declines in weight , potentially marking a ne